The clinical effects of dual MCT1 and MCT4 inhibition with different doses of syrosingopine were evaluated in primary BM mononuclear cells derived directly and fresh from the BM aspirates of MM patients. The gene discussed is SLC16A3; the disease is Miyoshi myopathy.